Chinook Therapeutics Performance
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
The firm shows a Beta (market volatility) of 0.3, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Chinook Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Chinook Therapeutics is expected to be smaller as well. Chinook Therapeutics right now shows a risk of 0.0%. Please confirm Chinook Therapeutics treynor ratio, as well as the relationship between the expected short fall and day median price , to decide if Chinook Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Chinook Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Chinook Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 183.8 M |
Chinook |
Chinook Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,925 in Chinook Therapeutics on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Chinook Therapeutics or generate 0.0% return on investment over 90 days. Chinook Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Chinook, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Chinook Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chinook Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Chinook Therapeutics, and traders can use it to determine the average amount a Chinook Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| KDNY |
Based on monthly moving average Chinook Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Chinook Therapeutics by adding Chinook Therapeutics to a well-diversified portfolio.
Chinook Therapeutics Fundamentals Growth
Chinook Stock prices reflect investors' perceptions of the future prospects and financial health of Chinook Therapeutics, and Chinook Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Chinook Stock performance.
| Return On Equity | -0.57 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (39.98) % | |||
| Current Valuation | 2.64 B | |||
| Shares Outstanding | 67.05 M | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 27.90 X | |||
| Revenue | 6.13 M | |||
| EBITDA | (164.2 M) | |||
| Cash And Equivalents | 362.61 M | |||
| Cash Per Share | 5.76 X | |||
| Total Debt | 39.44 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 5.32 X | |||
| Cash Flow From Operations | (117.48 M) | |||
| Earnings Per Share | (3.24) X | |||
| Total Asset | 574.08 M | |||
| Retained Earnings | (419.63 M) | |||
About Chinook Therapeutics Performance
Evaluating Chinook Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Chinook Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Chinook Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. Chinook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 138 people.Things to note about Chinook Therapeutics performance evaluation
Checking the ongoing alerts about Chinook Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Chinook Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Chinook Therapeutics is not yet fully synchronised with the market data | |
| Chinook Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 6.13 M. Net Loss for the year was (187.87 M) with loss before overhead, payroll, taxes, and interest of (135.08 M). | |
| Chinook Therapeutics currently holds about 362.61 M in cash with (117.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.76. | |
| Over 97.0% of the company shares are owned by institutional investors |
- Analyzing Chinook Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Chinook Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Chinook Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Chinook Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Chinook Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Chinook Therapeutics' stock. These opinions can provide insight into Chinook Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |